Ironwood Pharmaceuticals, Inc. — FY 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. The filing was signed February 29, 2012. Ironwood is a clinical-stage pharmaceutical company whose revenue came from collaboration and license arrangements; it had no product sales.
Business context and key developments
- Linaclotide, Ironwood’s lead GC-C agonist for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC), is its only candidate with clinical proof of concept. The FDA accepted the U.S. NDA for review in October 2011; the expected PDUFA target action date was June 2012. Almirall submitted an EU application for IBS-C in September 2011.
- In the four Phase 3 trials, linaclotide met primary and secondary endpoints. Diarrhea was the most frequently reported adverse event (14%–20% of treated patients) and led to discontinuation in 3%–6%.
- Ironwood shares U.S. linaclotide development and commercialization costs and profits equally with Forest. Almirall and Astellas hold rights in specified international territories.
- Other programs were at early development or discovery stages. IW-9179 was in early development for painful small-intestinal disorders.
Financial performance
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Collaborative arrangements revenue | $65.9 million | $43.9 million |
| Research and development expense | $86.1 million | $77.5 million |
| General and administrative expense | $45.9 million | $27.2 million |
| Total operating expenses | $132.0 million | $104.6 million |
| Loss from operations | $66.1 million | $60.8 million |
| Net loss attributable to Ironwood | $64.9 million | $53.0 million |
| Net loss per share, basic and diluted | $0.65 | $0.59 |
| Cash, cash equivalents and available-for-sale securities at year-end | $164.0 million | $248.0 million |
| Net cash used in operating activities | $75.2 million | $67.9 million |
Margins: No product gross margin was reported because the company had no product sales. Operating loss was approximately 100% of collaboration revenue in 2011, versus approximately 139% in 2010.
At year-end, current assets were $167.6 million and current liabilities were $65.1 million; working capital excluding deferred revenue was $138.7 million. Long-term debt was zero. Capital lease obligations totaled $0.7 million. Total liabilities were $99.1 million and stockholders’ equity was $109.9 million.
Changes, cash and unusual items
- Revenue rose 50.2%, mainly reflecting $20 million of Forest milestones for FDA acceptance of the IBS-C and CC NDA, recognized in full under the milestone accounting method adopted in 2011. A revised estimate of the Almirall development period added approximately $5 million of 2011 revenue.
- Operating expenses rose 26.2%. R&D increased 11.2%; G&A increased 69.0%, reflecting hiring and preparation for potential commercialization. The operating loss widened, and net loss increased versus 2010, which included a gain on the sale of Microbia.
- Fourth-quarter 2011 revenue was $32.2 million and net loss was $7.0 million, compared with revenue of $16.8 million and net loss of $11.7 million in fourth-quarter 2010.
- Operating cash use increased to $75.2 million. Investing activities provided $115.1 million, mainly from investment maturities and sales; financing activities provided $3.1 million. Cash and investments fell by $84.0 million year over year.
- In February 2012, after year-end, Ironwood raised approximately $85.3 million net through a Class A common stock offering. Management said cash resources, potential collaborator milestones and the offering proceeds were expected to fund operations through anticipated commercialization of linaclotide, subject to risks and forecast assumptions.
Outlook, risks and contingencies
- Management expected substantial losses for several years, continued significant R&D spending, and higher expenses to build commercialization capabilities. The filing provides no quantified sales or earnings guidance.
- Regulatory approval and commercial success of linaclotide were uncertain; approval could be delayed, limited by indication or labeling, or denied. Acceptance of the NDA did not assure approval. The FDA stated it would not schedule an advisory committee meeting.
- Commercial prospects depended on market adoption, reimbursement and pricing, competition, and partner execution. Manufacturing is outsourced, and the filing noted that commercial-scale drug-product capacity had not yet been demonstrated.
- Contractual obligations totaled $106.3 million, including $58.7 million of commercial supply commitments and $46.9 million of operating lease obligations. The company also disclosed future contingent milestone and royalty payments under collaboration agreements.
- The company reported no material legal proceedings. Management and the auditor concluded internal control over financial reporting was effective as of December 31, 2011; the financial statement audit opinion was unqualified.
Investor facts to verify
- FDA and EMA decisions, final labels, timing, and any required post-approval studies for linaclotide.
- Commercial launch readiness, manufacturing capacity and supply commitments, partner cost-sharing, and reimbursement access.
- Cash burn, the use of February 2012 offering proceeds, and the assumptions underlying management’s liquidity runway.
- How much collaboration revenue reflects milestones and accounting estimates rather than recurring product sales.
- Potential dilution from outstanding options and the governance implications of the dual-class share structure.